Efficacy and safety of mometasone furoate therapy versus cetirizine in adults with seasonal allergic rhinitis in a real-world clinical setting
DOI: 10.32364/2587-6821-2024-8-3-3
E.V. Churyukina1,2, I.V. Gamova3
1Rostov State Medical University, Rostov-on-Don, Russian Federation
2Kuban State Medical University, Krasnodar, Russian Federation
3V.I. Razumovskiy Saratov State Medical University, Saratov, Russian Federation
Background: both H1-histamine blockers and intranasal corticosteroids are recommended as step 2 pharmacotherapy for allergic rhinitis (AR).
Aim: to compare cetirizine and mometasone furoate (nasal spray) for AR treatment in patients requiring step 2 therapy in real-world clinical practice.
Patients and Methods: this study enrolled 160 patients aged 18–75 years suffering from AR with pollen sensitization and requiring step 2 of therapy. The study was observational, open-label, comparative, and non-interventional. The patients were divided into two groups: main group (MG; n=80) who received over-the-counter medicine mometasone furoate (nasal spray) 200 µg/day regimen and comparison group (CG; n=80) who received cetirizine 10 mg/day orally for 1 month±2 days. Patients had three office visits. Each visit included a physical examination, anterior rhinoscopy, and self-assessment using the visual analog scale (VAS). Both patients and physicians completed the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).
Results: treatment efficacy was excellent (0-1 VAS score) in 52 (65%) patients in the CG and in 76 patients in the MG (95%, p<0.05). Treatment efficacy was good (2-5 VAS scores) in 12 (15%) patients in the CG and in 4 (5%) patients in the MG. The study found that 5% of patients in the CG reported satisfactory results compared to 0% in the MG. Additionally, a significant difference (p<0.001) in the reduction of the RQLQ score was reported among patients who experienced an improvement in quality of life by day 14 of treatment in the CG (-80.3±19.3) and MG (-113.3±34.7). The effectiveness of mometasone furoate (200 µg/day) as a monotherapy for 4 weeks was found to be superior to cetirizine treatment (10 mg/day). Additionally, it was associated with a greater improvement in quality of life and better treatment tolerability due to fewer adverse events.
Conclusions: mometasone furoate (nasal spray) can be recommended as a monotherapy for adults with mild to moderate AR.
Keywords: seasonal allergic rhinitis, mometasone furoate, cetirizine, intranasal corticosteroids, oral antihistamines.
FOR CITATION: Churyukina E.V., Gamova I.V. Efficacy and safety of mometasone furoate therapy versus cetirizine in adults with seasonal allergic rhinitis in a real-world clinical setting. Russian Medical Inquiry. 2024;8(3):132–142 (in Russ.). DOI: 10.32364/2587-6821-2024-8-3-3.
About the authors:
Ella V. Churyukina — C. Sc. (Med.), Associate Professor, Head of the Division of Allergic and Autoimmune Diseases, Rostov State Medical University; 29, Nakhichevanskiy lane, Rostov-on-Don, 344022, Russian Federation; associate professor of the Department of Clinical Immunology, Allergy, and Laboratory Diagnostics, Kuban State Medical University; 4, Mitrofan Sedin str., Krasnodar, 350063, Russian Federation; ORCID iD 0000-0001-6407-6117.
Inna V. Gamova — C. Sc. (Med.), Associate Professor, Interim Head of the Department of Clinical Immunology and Allergy, V.I. Razumovskiy Saratov State Medical University; 112, Bolshaya Kazach'ya str., Saratov, 410012, Russian Federation; ORCID iD 0000-0002-0128-5883.
Contact information: Ella V. Churyukina, e-mail: echuryukina@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 08.02.2024.
Revised 04.03.2024.
Accepted 27.03.2024.
2. Bousquet J., Schünemann H.J., Togias A. et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70–80.e3. DOI: 10.1016/j.jaci.2019.06.049.
3. Aït-Khaled N., Pearce N., Anderson H.R. et al. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy. 2009;64(1):123–148. DOI: 10.1111/j.1398-9995.2008.01884.x.
4. Bousquet P.J., Leynaert B., Neukirch F. et al. Geographical distribution of atopic rhinitis in the European Community Respiratory Health Survey I. Allergy. 2008;63(10):1301–1309. DOI: 10.1111/j.1398-9995.2008.01824.x.
5. Bousquet J., Khaltaev N., Cruz A.A. et al. ARIA update 2008: allergic rhinitis and its effect on asthma. Allergologie. 2009;32(8):306–319. DOI: 10.5414/ALP32306.
6. Leger D., Bonnefoy B., Pigearias B. et al. Poor sleep is highly associated with house dust mite allergic rhinitis in adults and children. Allergy Asthma Clin Immunol. 2017;13:36. DOI: 10.1186/s13223-017-0208-7.
7. Vandenplas O., Vinnikov D., Blanc P.D. et al. Impact of Rhinitis on Work Productivity: A Systematic Review. J Allergy Clin Immunol Pract. 2018;6(4):1274–1286.e9. DOI: 10.1016/j.jaip.2017.09.002.
8. Devillier P., Bousquet J., Salvator H. et al. In allergic rhinitis, work, classroom and activity impairments are weakly related to other outcome measures. Clin Exp Allergy. 2016;46(11):1456–1464. DOI: 10.1111/cea.12801.
9. Cingi C., Gevaert P., Mösges R. et al. Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report. Clin Transl Allergy. 2017;7:17. DOI: 10.1186/s13601-017-0153-z.
10. Bousquet J., Neukirch F., Bousquet P.J. et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006;117(1):158–62. DOI: 10.1016/j.jaci.2005.09.047.
11. Zuberbier T., Lötvall J., Simoens S. et al. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy. 2014;69(10):1275–1279. DOI: 10.1111/all.12470.
12. Colás C., Brosa M., Antón E. et al. Rhinoconjunctivitis Committee of the Spanish Society of Allergy and Clinical Immunology. Estimate of the total costs of allergic rhinitis in specialized care based on real-world data: the FERIN Study. Allergy. 2017;72(6):959–966. DOI: 10.1111/all.13099.
13. Braunstahl G.J., Fokkens W. Nasal involvement in allergic asthma. Allergy. 2003;58(12):1235–1243. DOI: 10.1046/j.0105-4538.2003.00354.x.
14. Weiner J.M., Abramson M.J., Puy R.M. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998;317(7173):1624–1629. DOI: 10.1136/bmj.317.7173.1624.
15. Juel-Berg N., Darling P., Bolvig J. et al. Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: A systematic review and meta-analysis. Am J Rhinol Allergy. 2017;31(1):19–28. DOI: 10.2500/ajra.2016.30.4397.
16. Sousa-Pinto B., Vieira R.J., Brozek J. et al. Intranasal antihistamines and corticosteroids in the treatment of allergic rhinitis: a systematic review and meta-analysis protocol. BMJ Open. 2023;13(11):e076614. DOI: 10.1136/bmjopen-2023-076614.
17. Grzelewska-Rzymowska I., Kalinowska-Graczyk M., Kopczyński J., Rozniecki J. Cetirizine for treating allergic seasonal rhinitis. Pneumonol Alergol Pol. 1992;60(11–12):28–31 (in Polish). PMID: 1303775.
18. Barnes C.L., McKenzie C.A., Webster K.D., Poinsett-Holmes K. Cetirizine: a new, nonsedating antihistamine. Ann Pharmacother. 1993;27(4):464–470. DOI: 10.1177/106002809302700414.
19. Molkhou P., Billardon M., Jouan A.M., Fondarai J. Multicenter hospital study on the efficacy of Zyrtec (R) (cetirizine) compared to a placebo, in the treatment of perennial allergic rhinitis in 254 adolescents aged 12–15. Allerg Immunol (Paris). 1995;27(8):300–306 (in French). PMID: 8851038.
20. Murray J.J., Nathan R.A., Bronsky E.A. et al. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc. 2002;23(6):391–398. PMID: 12528605.
21. Zhang L., Cheng L., Hong J. The clinical use of cetirizine in the treatment of allergic rhinitis. Pharmacology. 2013;92(1–2):14–25. DOI: 10.1159/000351843.
22. Agrawal V.K., Patel S., Petare A.U., Veligandla K.C. Improving the Quality of Life in the Management of Allergic Rhinitis: New Perspective on Cetirizine. J Assoc Physicians India. 2022;70(6):11–12. DOI: 10.5005/japi-11001-0026.
23. Urdaneta E.R., Patel M.K., Franklin K.B. et al. Assessment of Different Cetirizine Dosing Strategies on Seasonal Allergic Rhinitis Symptoms: Findings of Two Randomized Trials. Allergy Rhinol (Providence). 2018;9:2152656718783630. DOI: 10.1177/2152656718783630.
24. Чурюкина Э.В. Роль и место интраназальных кортикостероидов в лечении аллергического ринита на современном этапе. РМЖ. 2019;27(3):51–56.
Churyukina Е.V. Role and place of intranasal corticosteroids in the treatment of allergic rhinitis at the present stage. RMJ. 2019;27(3):51–56 (in Russ.).
25. Penagos M., Compalati E., Tarantini F. et al. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy. 2008;63(10):1280–1291. DOI: 10.1111/j.1398-9995.2008.01808.x.
26. Yamamoto H., Yonekura S., Sakurai D. et al. Comparison of nasal steroid with antihistamine in prophylactic treatment against pollinosis using an environmental challenge chamber. Allergy Asthma Proc. 2012;33(5):397–403. DOI: 10.2500/aap.2012.33.3594.
27. Чурюкина Э.В., Уханова О.П. Современные лечебно-диагностические инструменты оценки назальной функции и нарушений обоняния у пациентов с аллергическим ринитом. Алгоритм комплексной терапии. РМЖ. 2020;28(12):56–60.
Churyukina E.V., Ukhanova O.P. Modern medical and diagnostic tools for assessing nasal function and olfactory disorders in patients with allergic rhinitis. Complex therapy algorithm. RMJ. 2020;12:56–60 (in Russ.).
28. Schafer T., Schnoor M., Wagenmann M. et al. Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. Rhinology. 2011;49(3):272–280. DOI: 10.4193/Rhino10.170.
29. Lumry W.R. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999;104(4 Pt 1):S150–158. DOI: 10.1016/s0091-6749(99)70311-8.
30. Berkowitz R.B., Bernstein D.I., LaForce C. et al. Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy. 1999;54(1):64–69. DOI: 10.1034/j.1398-9995.1999.00713.x.
31. Anolik R., Pearlman D., Teper A., Gates D. Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents. Allergy Asthma Proc. 2009;30(4):406–412. DOI: 10.2500/aap.2009.30.3238.
32. Baena-Cagnani C.E., Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr Med Res Opin. 2010;26(9):2047–2055. DOI: 10.1185/03007995.2010.487661.
33. Grossman J., Gates D. Mometasone furoate nasal spray for the treatment of elderly patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2010;104(5):452–453. DOI: 10.1016/j.anai.2010.03.007.
34. Passali D., Spinosi M.C., Crisanti A., Bellussi L.M. Mometasone furoate nasal spray: a systematic review. Multidiscip Respir Med. 2016;11:18. DOI: 10.1186/s40248-016-0054-3.
35. Prenner B.M., Lanier B.Q., Bernstein D.I. et al. Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol. 2010;125(6):1247–1253.e5. DOI: 10.1016/j.jaci.2010.03.004.
36. Juel-Berg N., Darling P., Bolvig J. et al. Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: A systematic review and meta-analysis. Am J Rhinol Allergy. 2017;31(1):19–28. DOI: 10.2500/ajra.2016.30.4397.
37. Cetin B., Saglam O., Dursun E., Karapinar U. Comparison of Mometazon Furoate to Cetirizin for Symptom Severity Control and QOL in Allergic Rhinitis. Otolaryngology Head and Neck Surgery. 2014;151(1):249. DOI: 10.1177/0194599814541629a352.
38. Чурюкина Э.В., Уханова О.П., Голошубова Е.А. Аэропалинологический мониторинг воздушной среды в Ростовской области: результаты сезона палинации 2019 года. Российский аллергологический журнал. 2020;4(17):57–65. DOI: 10.36691/RJA1387.
Churyukina E.V., Ukhanova O.P., Goloshubova E.A. Aeropalinological monitoring of the air environment in the Rostov region: results of the 2019 palination season. Russian Allergological Journal. 2020;4(17):57–65 (in Russ.). DOI: 10.36691/RJA1387.
39. Чурюкина Э.В., Назарова Е.В. Особенности грибкового спектра воздушной среды в Ростовской области по результатам аэропалинологического мониторинга 2019 года. Российский аллергологический журнал. 2021;18(2):32–45. DOI: 10.36691/RJA1415.
Churyukina E.V., Nazarova E.V. Features of the fungal spectrum in the air environment in the Rostov region according to the results aeropalynologic monitoring 2019. Russian Journal of Allergy. 2021;18(2):32–45 (in Russ.). DOI: 10.36691/RJA1415.
40. Juniper E.F., Guyatt G.H. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77–83. DOI: 10.1111/j.1365-2222.1991.tb00807.x.
41. Чурюкина Э.В., Сизякина Л.П. Патогенетические аспекты формирования различных вариантов бронхиальной астмы. Российский аллергологический журнал. 2017;14(1):194–196.
Churyukina E.V., Sizyakina L.P. Pathogenetic aspects of the formation of various variants of bronchial asthma. Russian Journal of Allergy. 2017;14(1)194–196 (in Russ.).
42. Magyar P., Herjavecz I., Hirschberg A. et al. Effectiveness and tolerability of the glucocorticoid mometasone furoate given as nasal spray in seasonal allergic rhinitis. Orv Hetil. 2000;141(25):1407–1411 (in Hungarian). PMID: 10934885.
43. Du Q., Zhou Y. Placebo-controlled assessment of somnolence effect of cetirizine: a meta-analysis. Int Forum Allergy Rhinol. 2016;6(8):871–879. DOI: 10.1002/alr.21746.
44. Day J.H., Briscoe M., Widlitz M.D. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol. 1998;101(5):638–645. DOI: 10.1016/S0091-6749(98)70172-1.
45. Mann R.D., Pearce G.L., Dunn N., Shakir S. Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. BMJ. 2000;320(7243):1184–1186. DOI: 10.1136/bmj.320.7243.1184.
46. Свистушкин В.М., Никифорова Г.Н., Шевчик Е.А. и др. Возможности интраназальных препаратов в лечении больных медикаментозным ринитом. Медицинский Совет. 2023;7:152–159. DOI: 10.21518/ms2023-117.
Svistushkin V.M., Nikiforova G.N., Shevchik E.A. et al. Intranasal drugs possibilities in the treatment of patients with rhinitis medicamentosa. Medical Council. 2023;7:152–159 (in Russ.). DOI: 10.21518/ms2023-117.
47. Ozdemir P.G., Karadag A.S., Selvi Y. et al. Assessment of the effects of antihistamine drugs on mood, sleep quality, sleepiness, and dream anxiety. Int J Psychiatry Clin Pract. 2014;18(3):161–168. DOI: 10.3109/13651501.2014.907919.
48. Portnoy J.M., Dinakar C. Review of cetirizine hydrochloride for the treatment of allergic disorders. Expert Opin Pharmacother. 2004;5(1):125–135. DOI: 10.1517/14656566.5.1.125. PMID: 14680442.
49. Kim J.H., Park S.H., Moon Y.W. et al. Histamine H1 receptor induces cytosolic calcium increase and aquaporin translocation in human salivary gland cells. J Pharmacol Exp Ther. 2009;330(2):403–412. DOI: 10.1124/jpet.109.153023.
50. Курбачева О.М., Носуля Е.В. Мета-анализ исследований эффективности и безопасности интраназальных стероидов. Российский аллергологический журнал. 2009;2;76–88. DOI: 10.36691/RJA1068.
Kurbacheva O.M., Nosulya E.V. Meta-analysis of the efficacy and safety intranasal corticosteroids. Clinical advantage and unresolved problems. Russian Journal of Allergy. 2009;2;76–88 (in Russ.). DOI: 10.36691/RJA1068.
51. Trangsrud A.J., Whitaker A.L., Small R.E. Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy. 2002;22(11):1458–1467. DOI: 10.1592/phco.22.16.1458.33692.
52. Wu E.L., Harris W.C., Babcock C.M. et al. Epistaxis Risk Associated with Intranasal Corticosteroid Sprays: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2019;161(1):18–27. DOI: 10.1177/0194599819832277.
53. Кочетков П.А., Лопатин А.С. Лечение полипозного риносинусита. Мометазона фуроат. Обзор литературы. Российский аллергологический журнал. 2009;6(4):3–11.
Kochetkov P.A., Lopatin A.S. Treatment of polypous rhinosinusitis. Mometasone furoate. Review Russian Journal of Allergy. 2009;6(4):3–11 (in Russ.). DOI: 10.36691/RJA1017.
54. Ganesh V., Banigo A., McMurran A.E.L. et al. Does intranasal steroid spray technique affect side effects and compliance? Results of a patient survey. J Laryngol Otol. 2017;131(11):991–996. DOI: 10.1017/S0022215117002080.
55. Dibildox J. Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: results of recent clinical trials. J Allergy Clin Immunol. 2001;108(1 Suppl):S54–58. DOI: 10.1067/mai.2001.115567.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
